Abstract
ObjectiveInsulin-like growth factor-1 (IGF-1) has been associated with cardiovascular risk factors and atherosclerosis. The aim of the present study was to evaluate the prognostic value of IGF-1 levels in patients with acute ischemic stroke (AIS).MethodsAll patients with first-ever AIS from August 1, 2012 to August 31, 2013 were recruited to participate in the study. Clinical data were collected. The National Institutes of Health Stroke Scale (NIHSS) score was assessed on admission blinded to serum IGF-1 levels. For the assessment of functional outcome at 90 days Modified Rankin Scale (mRS) was used. On admission, serum IGF-1 levels were determined by chemiluminescence immunoassay. The influence of IGF-1 levels on functional outcome and death was assessed by multivariate logistic regression analysis.ResultsPatients with an unfavorable outcomes and non-survivors had significantly decreased serum IGF-1 levels on admission (P<0.0001 for both). IGF-1 was an independent prognostic marker of functional outcome and death [odds ratio 0.89 (0.84–0.93) and 0.90 (0.84–0.95), respectively, P<0.0001 for both, adjusted for age, NIHSS score and other predictors] in patients with ischemic stroke. Serum IGF-1 levels ≤130 ng/mL was as an value indicator for unfavorable functional outcome (OR 3.31, 95% CI:1.87–5.62; P<0.0001), after adjusting for other significant confounders.ConclusionsWe reported a significant association between low serum IGF-1 levels and unfavorable functional outcome and death.
Highlights
Stroke is the second most common cause of death and leading cause of adult disability in China [1]
Evidence has accrued to demonstrate that the insulin-like growth factor 1 (IGF-1) play an important role in cancer [3], Alzheimer’s disease [4], frail [5], oronary atherosclerosis and restenosis [6], ostnatal brain development and in neonatal hypoxia–ischaemia [7], and diabetes associated dementia [8]
Serum Insulin-like growth factors (IGFs)-1 levels #130 ng/mL was as an value indicator for unfavorable functional outcome, after adjusting for other significant confounders
Summary
Stroke is the second most common cause of death and leading cause of adult disability in China [1]. Biomarkers are attracting increasing attention as potential predictors of outcome in stroke. Measurable biomarkers to predict illness development, outcome and mortality are pivotal for optimized care and allocation of healthcare resources. A prompt identification of stroke patients at increased risk for adverse outcome interventions could be targeted to those most likely to benefit. Insulin-like growth factors (IGFs) are peptide hormones that have significant structural homology with insulin. Evidence has accrued to demonstrate that the IGF-1 play an important role in cancer [3], Alzheimer’s disease [4], frail [5], oronary atherosclerosis and restenosis [6], ostnatal brain development and in neonatal hypoxia–ischaemia [7], and diabetes associated dementia [8]. Roubenoff et al [9] found that greater levels of IGF-1 are associated with decreased mortality in community-dwelling elderly adults
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
